Trial
NCT02806960
A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Eli Lilly and Company
Collaborators
Locemia Solutions ULC
Condition
Diabetes Mellitus, Type 1
Intervention
Nasal Glucagon
Why stopped
Drug delivery was below target dose due to partial obstruction by aggregated particles.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-13